Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 1999
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Key products include EPOGEN (Epoetin alfa), NEUPOGEN (Filgrastim), and INFERGEN (Interferon alfacon-1).
Key Financial Metrics
| Metric (in millions) | Q1 1999 | Q1 1998 |
|---|---|---|
| Total Revenues | $745.5 | $605.4 |
| Net Income | $247.2 | $187.3 |
| Diluted EPS | $0.46 | $0.35 |
| Operating Cash Flow | $200.7 | $292.8 |
| Cash & Equivalents | $114.1 | $104.6 |
| Total Debt (Long-term + Current) | $322.9 | $328.7 |
| Effective Tax Rate | 28.5% | 30.0% |
Liquidity: Total cash, cash equivalents, and marketable securities stood at $1,318 million as of March 31, 1999.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 23% to $745.5 million, driven primarily by a 21% increase in product sales ($688.3 million).
- Product Performance:
- EPOGEN: Sales rose 30% to $394.9 million due to higher dosing and growth in the U.S. dialysis population following HCFA reimbursement policy revisions.
- NEUPOGEN: Sales increased 10% to $287 million, aided by U.S. market growth and favorable currency effects, though constrained by cost containment pressures.
- INFERGEN: Sales surged 425% to $6.3 million following its 1997 launch.
- Expense Increases: Operating expenses rose 19% to $416.1 million. R&D expenses increased 23% ($35.5 million) due to collaboration costs and staff expansion. SG&A increased 18% ($19.8 million) due to marketing and consulting fees.
- Stock Repurchases: The company repurchased 2.9 million shares for $202.5 million, a decrease in volume and cost compared to the prior year's $337.8 million.
Guidance, Outlook, and Risks
Financial Outlook
- 1999 Sales Growth: Expected to be in the mid-to-high teens.
- 1999 EPS Guidance: Projected between $1.80 and $1.85.
- Capital Expenditures: Anticipated to be $300 million to $400 million for 1999.
Key Risks and Contingencies
- Johnson & Johnson Arbitration: Ongoing disputes regarding "spillover" sales of EPOGEN/PROCRIT and recovery of arbitration costs. While Amgen won the methodology dispute, J&J is contesting cost recovery. Amgen estimates a potential reduction in recoverable fees of $12 million to $17 million. No benefit has been recognized due to uncertainty.
- Reimbursement Policy: EPOGEN sales are sensitive to federal government reimbursement rates. A proposed 10% cut in Medicare reimbursement for EPOGEN is under consideration for the FY2000 budget. NEUPOGEN faces potential Medicare Part B coverage challenges.
- Year 2000 Compliance: Amgen is not yet fully compliant. Estimated total costs range from $40 million to $60 million. The company is behind schedule on some projects and warns that failure of suppliers or payors to be compliant could materially affect operations.
- Legal Proceedings: Active litigation includes patent disputes with Genentech and the FoxMeyer Health Corporation bankruptcy suit.
Investor Verification Checklist
- Verify the impact of the proposed 10% Medicare reimbursement cut on EPOGEN sales volume and pricing.
- Monitor the resolution of the Johnson & Johnson arbitration regarding cost recovery and potential license termination claims.
- Assess the progress of the Year 2000 compliance program, specifically the remediation of critical manufacturing and financial systems.
- Review the competitive landscape for NEUPOGEN in the EU and the impact of cost containment on U.S. growth.
- Confirm the sustainability of the 30% EPOGEN growth rate given the recent HCFA policy changes.